Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    127
    ...
ATC Name B/G Ingredients Dosage Form Price
C09CA08 VOTUM B Olmesartan medoxomil - 40mg 40mg Tablet, film coated 1,032,071 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 40mg 40mg Tablet, film coated 721,643 L.L
C09CA07 MICARDIS B Telmisartan - 40mg 40mg Tablet 760,615 L.L
C09CA07 TELMICARD 40 G Telmisartan - 40mg 40mg Tablet 659,123 L.L
C09CA07 TOLURA G Telmisartan - 40mg 40mg Tablet 532,162 L.L
C09CA07 MICARDIS B Telmisartan - 80mg 80mg Tablet 998,475 L.L
C09CA07 ARBIVASTEL G Telmisartan - 80mg 80mg Tablet 667,890 L.L
C09CA07 TELMICARD 80 G Telmisartan - 80mg 80mg Tablet 865,179 L.L
C09CA07 TOLURA G Telmisartan - 80mg 80mg Tablet 698,798 L.L
C09CA06 ATACAND B Candesartan cilexetil - 8mg 8mg Tablet 526,786 L.L
C09CA06 BLOPRESS B Candesartan cilexetil - 8mg 8mg Tablet 847,965 L.L
C09CA06 ANDESART 8 G Candesartan cilexetil - 8mg 8mg Tablet 498,566 L.L
C09CA06 ARKANDA 8 G Candesartan cilexetil - 8mg 8mg Tablet 639,925 L.L
C09CA06 CANDESARTAN BIOGARAN G Candesartan cilexetil - 8mg 8mg Tablet, scored 434,061 L.L
C09CA06 ATACAND B Candesartan cilexetil - 16mg 16mg Tablet 705,517 L.L
C09CA06 BLOPRESS B Candesartan cilexetil - 16mg 16mg Tablet 1,131,515 L.L
C09CA06 ANDESART 16 G Candesartan cilexetil - 16mg 16mg Tablet 665,202 L.L
C09CA06 ARKANDA 16 G Candesartan cilexetil - 16mg 16mg Tablet 700,078 L.L
C09CA06 CANDESARTAN BIOGARAN G Candesartan cilexetil - 16mg 16mg Tablet, scored 434,061 L.L
C09CA06 CANDESARTAN BIOGARAN G Candesartan cilexetil - 32mg 32mg Tablet, scored 434,061 L.L
C09CA04 APROVEL B Irbesartan - 150mg 150mg Tablet, film coated 651,764 L.L
C09CA04 APROVEL B Irbesartan - 150mg 150mg Tablet, film coated 651,764 L.L
C09CA04 ANDARAN G Irbesartan - 150mg 150mg Tablet, film coated 904,612 L.L
C09CA04 CONVERIUM G Irbesartan - 150mg 150mg Tablet 585,915 L.L
C09CA04 GIZLAN G Irbesartan - 150mg 150mg Tablet, film coated 748,520 L.L
C09CA04 IBECARD 150- IPS G Irbesartan - 150mg 150mg Tablet, film coated 564,414 L.L
C09CA04 IRBAVEL 150 G Irbesartan - 150mg 150mg Tablet, film coated 564,414 L.L
C09CA04 IRBESARTAN ARROW G Irbesartan - 150mg 150mg Tablet 470,345 L.L
C09CA04 ZIOREL G Irbesartan - 150mg 150mg Tablet, film coated 575,933 L.L
C09CA04 APROVEL B Irbesartan - 300mg 300mg Tablet, film coated 651,764 L.L
    ...
    127
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025